U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. US Vascular LLC - 554761 - 03/18/2020
  1. Warning Letters

CLOSEOUT LETTER

US Vascular LLC MARCS-CMS 554761 —

Product:
Medical Devices

Recipient:
Recipient Name
Mr. Galen T. Spooner
Recipient Title
Owner
US Vascular LLC

PO Box 199
Beaverton, OR 97075
United States

mailto:gus@vasculab.com
Issuing Office:
Office of Medical Device and Radiological Health Division 3/West

United States


Dear Mr. Spooner:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter [WL CMS 554761 dated June 7, 2018]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu
Director of Compliance Branch
Office of Medical Device and Radiological Health
Division 3/West

Back to Top